Literature DB >> 32768596

Epoxygenase-Derived Epoxyeicosatrienoic Acid Mediators Are Associated With Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Fibrosis.

Ashwini Arvind1, Stephanie A Osganian2, Julia A Sjoquist2, Kathleen E Corey3, Tracey G Simon4.   

Abstract

Entities:  

Year:  2020        PMID: 32768596      PMCID: PMC7725909          DOI: 10.1053/j.gastro.2020.08.001

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  8 in total

1.  Characterization of the Cytochrome P450 epoxyeicosanoid pathway in non-alcoholic steatohepatitis.

Authors:  Michael A Wells; Kimberly C Vendrov; Matthew L Edin; Brian C Ferslew; Weibin Zha; Bobbie K H Nguyen; Rachel J Church; Fred B Lih; Laura M DeGraff; Kim L R Brouwer; A Sidney Barritt; Darryl C Zeldin; Craig R Lee
Journal:  Prostaglandins Other Lipid Mediat       Date:  2016-07-09       Impact factor: 3.072

2.  Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis.

Authors:  Rohit Loomba; Oswald Quehenberger; Aaron Armando; Edward A Dennis
Journal:  J Lipid Res       Date:  2014-11-17       Impact factor: 5.922

3.  Epoxyeicosatrienoic intervention improves NAFLD in leptin receptor deficient mice by an increase in PGC1α-HO-1-PGC1α-mitochondrial signaling.

Authors:  Marco Raffaele; Lars Bellner; Shailendra P Singh; Gaia Favero; Rita Rezzani; Luigi Fabrizio Rodella; John R Falck; Nader G Abraham; Luca Vanella
Journal:  Exp Cell Res       Date:  2019-04-27       Impact factor: 3.905

4.  Cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids contribute to insulin sensitivity in mice and in humans.

Authors:  Mahesha H Gangadhariah; Blake W Dieckmann; Louise Lantier; Li Kang; David H Wasserman; Manuel Chiusa; Charles F Caskey; Jaime Dickerson; Pengcheng Luo; Jorge L Gamboa; Jorge H Capdevila; John D Imig; Chang Yu; Ambra Pozzi; James M Luther
Journal:  Diabetologia       Date:  2017-03-28       Impact factor: 10.122

5.  Epoxyeicosanoids promote organ and tissue regeneration.

Authors:  Dipak Panigrahy; Brian T Kalish; Sui Huang; Diane R Bielenberg; Hau D Le; Jun Yang; Matthew L Edin; Craig R Lee; Ofra Benny; Dayna K Mudge; Catherine E Butterfield; Akiko Mammoto; Tadanori Mammoto; Bora Inceoglu; Roger L Jenkins; Mary A Simpson; Tomoshige Akino; Fred B Lih; Kenneth B Tomer; Donald E Ingber; Bruce D Hammock; John R Falck; Vijaya L Manthati; Arja Kaipainen; Patricia A D'Amore; Mark Puder; Darryl C Zeldin; Mark W Kieran
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-29       Impact factor: 11.205

6.  Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice.

Authors:  Craig R Lee; John D Imig; Matthew L Edin; Julie Foley; Laura M DeGraff; J Alyce Bradbury; Joan P Graves; Fred B Lih; James Clark; Page Myers; A Ligon Perrow; Adrienne N Lepp; M Alison Kannon; Oline K Ronnekleiv; Nabil J Alkayed; John R Falck; Kenneth B Tomer; Darryl C Zeldin
Journal:  FASEB J       Date:  2010-05-21       Impact factor: 5.191

7.  The cytochrome P450 epoxygenase pathway regulates the hepatic inflammatory response in fatty liver disease.

Authors:  Robert N Schuck; Weibin Zha; Matthew L Edin; Artiom Gruzdev; Kimberly C Vendrov; Tricia M Miller; Zhenghong Xu; Fred B Lih; Laura M DeGraff; Kenneth B Tomer; H Michael Jones; Liza Makowski; Leaf Huang; Samuel M Poloyac; Darryl C Zeldin; Craig R Lee
Journal:  PLoS One       Date:  2014-10-13       Impact factor: 3.240

8.  Cytochrome P450-derived epoxyeicosatrienoic acids and coronary artery disease in humans: a targeted metabolomics study.

Authors:  Akinyemi Oni-Orisan; Matthew L Edin; John Andrew Lee; Michael A Wells; Erin S Christensen; Kimberly C Vendrov; Fred B Lih; Kenneth B Tomer; Xue Bai; Joan M Taylor; George A Stouffer; Darryl C Zeldin; Craig R Lee
Journal:  J Lipid Res       Date:  2015-11-10       Impact factor: 5.922

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.